乙型肝炎肝硬化患者的临床特征与抗病毒治疗模式变化

Clinical profiles and treatment patterns of patients with HBV-related liver cirrhosis

目的了解我国乙型肝炎肝硬化患者的临床特征和治疗模式及变化趋势。方法从CR-HepB系统提取历年相关数据,描述患者的一般临床资料、病毒学、血液学、生化、治疗用药信息,并分析其变化趋势。结果研究共纳入5263例乙型肝炎肝硬化患者,其中代偿期患者2013例(38.2%),失代偿期患者2752例(52.3%),未确定代偿或失代偿期患者498例(9.5%)。自2010年至2019年,诊断为乙型肝炎肝硬化时年龄≥50岁者由45.6%升至57.9%,HBeAg阳性率由47.4%降至35.8%,一线抗病毒药物(恩替卡韦和替诺福韦酯)选用比例由41.9%升至92.8%。结论我国乙型肝炎肝硬化患者的诊断年龄逐渐增高、HBeAg阳性率下降,一线抗病毒药物使用比例明显提高。

Objective To analyze the clinical profiles and treatment patterns of patients with hepatitis B virus(HBV)-related cirrhosis in real-world clinical setting in China.Methods The demographic,clinical and treatment data were analyzed from enrolled patients in China Registry of Hepatitis B.Results A total of 5263 patients with HBV-related liver cirrhosis were included in the study,including 2013(38.2%)patients with compensated status,2752 patients(52.3%)with decompensated status and 498 patients(9.5%)unspecified.From 2010 to 2019,the proportion of patients≥50 years old in those diagnosed with cirrhosis increased from 45.6%to 57.9%,the hepatitis B envelope antigen(HBeAg)positive rate decreased from 47.4%to 35.8%,and the use of the first-line antiviral drugs(entecavir or tenofovir)increased from 41.9%to 92.8%.Conclusion The real-world study demonstrated that the age of patients with diagnosis of cirrhosis gradually increased,the HBeAg positive rate gradually decreased,and the use of first-line antiviral drugs dramatically increased.